Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FROM TRIAL: In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP-related death and recurrence of TTP.

Original publication

DOI

10.1111/tme.12615

Type

Journal article

Journal

Transfus Med

Publication Date

06/2019

Volume

29

Pages

146 - 148

Keywords

RCT, caplacizumab, plasma exchange, thrombotic thrombocytopenic pupura